Recent Company News

• 07:05 PM ET Oct 19, 2025
  

  Taiho Pharmaceutical exercises option to develop and, if approved, commercialize casdatifan ($16.47, 0.00)

• 06:58 AM ET Oct 18, 2025
  

  Olema Pharmaceuticals announces updated data from Phase 1B/2 study of palazestrant in combination with ribociclib ($9.36, 0.00)

• 08:06 AM ET Oct 17, 2025
  

  Novartis announces Kisqali 5-year NATALEE data demonstrating 28% reduction in risk of recurrence in the broadest early breast cancer patient population (CHF 103.26, -1.08)

• 06:37 PM ET Oct 12, 2025
  

  Taiho Oncology & Cullinan Therapeutics present new data from CNS involvement cohort of REZILIENT2 study of zipalertinib in patients with advanced or metastatic NSCLC harboring EGFR ex20ins or uncommon non-ex20ins EGFR mutations at ESMO ($7.40, 0.00)

• 12:03 AM ET Oct 01, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:50 PM ET Sep 30, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 12:50 PM ET Sep 26, 2025
  

  White House says the latest pharmaceutical tariffs do not apply to countries with negotiated trade deals -- wires

• 08:15 PM ET Sep 25, 2025
  

  Trump says pharmaceutical products imported into US will be hit with 100% tariff starting 1-Oct - Truth Social post

• 09:49 AM ET Sep 25, 2025
  

  MicroPort Scientific holder Otsuka Holdings offers to sell 92.3M shares at HK$12.44-12.71/share - IFR (HK$13.52, 0.00)

• 07:43 AM ET Sep 20, 2025
  

  Otsuka, Lundbeck receive CRL from FDA for sNDA of REXULTI in combination with sertraline to treat adults with PTSD (¥8141.0000, 0)